🇺🇸 FDA
Patent

US 11326166

Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61K47/549

Quick answer

US patent 11326166 (Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/713, A61K47/549